
    
      Amendment 3 of the protocol reduced the dose of telcagepant to be administered from a single
      dose of 900 mg to a single dose of 600 mg. Pooled data from both the 600-mg and the 900-mg
      group wiil be utilized in the analyses. Also due to supply issues regarding the 300 mg
      telcagepant capsules, 280 mg telcagepant tablets with demonstrated bioequivalence to the 300
      mg telcagepant capsules, could be administered to participants enrolled after the
      implementation of Amendment 3.
    
  